Form 4: Annexon Director Thomas Wiggans Granted 55,000 Stock Options

Annexon, Inc. Director Thomas G. Wiggans was granted 55,000 stock options with an exercise price of $2.55, vesting on the earlier of June 5, 2026, or the next Annual Meeting.

Summary

• Thomas G. Wiggans, a Director of Annexon, Inc. (ANNX), was granted 55,000 stock options on June 5, 2025.
• The options have an exercise price of $2.55 per share.
• The options will vest 100% on the earlier of June 5, 2026 (the first anniversary of the grant date) or the next Annual Meeting following June 5, 2025, contingent on Mr. Wiggans' continuous service as a director.
• The expiration date for these options is June 5, 2035.
• Following this transaction, Mr. Wiggans directly beneficially owns 55,000 derivative securities (stock options).

Sentiment

Score: 6

Explanation: Neutral to slightly positive. It's a routine compensation event, but it signifies continued commitment from a director and aligns interests with shareholders. No negative implications.

Positives

• The grant of stock options to Director Thomas G. Wiggans aligns his interests with shareholders, incentivizing long-term performance and retention.
• The exercise price of $2.55 provides a clear benchmark for future stock performance relative to the grant.

Negatives

• No direct negatives are apparent from this specific Form 4 filing, as it reports a standard equity compensation grant.

Risks

• The vesting of the options is subject to Thomas G. Wiggans' continuous service as a director, meaning the options could be forfeited if his service ceases before the vesting date.
• The value of the options is dependent on Annexon, Inc.'s stock price exceeding the exercise price of $2.55, posing a market risk.

Future Outlook

This Form 4 filing indicates future alignment of a director's incentives with the company's long-term performance through equity compensation, with vesting contingent on continued service and the options expiring in 2035.

Management Comments

• No direct management comments or quotes are typically found in a Form 4 filing, as it is a transactional report.

Industry Context

The granting of stock options to directors is a common practice in the biotechnology and pharmaceutical industry, including companies like Annexon, Inc., to attract and retain talent, and to align management and director interests with shareholder value creation. This is a standard compensation mechanism.

Comparison to Industry Standards

• The grant of 55,000 stock options to a director is within the typical range for non-executive director equity compensation in the biotech sector, though the specific value depends on the company's market capitalization and stage of development.
• Similar grants are observed at peer companies for their non-executive directors, albeit the absolute number of options might vary based on their respective stock prices and compensation philosophies.
• The vesting schedule (one year or next annual meeting) is also a common practice to ensure continued service.

Stakeholder Impact

• Shareholders: The grant of stock options to a director aligns their interests with shareholders, as the options' value increases with the company's stock price, incentivizing efforts to enhance shareholder value.
• Employees: No direct impact on general employees from this specific director option grant.

Next Steps

• The stock options will vest on the earlier of June 5, 2026, or the next Annual Meeting following June 5, 2025, subject to continuous service.
• Thomas G. Wiggans may exercise these options at any time after vesting and before the expiration date of June 5, 2035, assuming the stock price is above the exercise price.

Key Dates

Recommendation

Keywords

Annexon Inc., ANNX, Form 4, Stock Options, Director Compensation, Equity Grant, Insider Transaction, Thomas Wiggans